{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:59:44Z","timestamp":1792814384460,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jaad.2024.02.039","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T17:13:13Z","timestamp":1709572393000},"page":"72-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2\/3 randomized trials"],"prefix":"10.1016","volume":"91","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"de Cuyper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jaad.2024.02.039_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/14737167.2014.914437","article-title":"Quality of life in psoriasis patients","volume":"14","author":"Augustin","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"8","key":"10.1016\/j.jaad.2024.02.039_bib2","first-page":"891","article-title":"The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study","volume":"146","author":"Kurd","year":"2010","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.02.039_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.biopsych.2014.10.014","article-title":"Meta-analysis of cytokines and chemokines in suicidality: distinguishing suicidal versus nonsuicidal patients","volume":"78","author":"Black","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.jaad.2024.02.039_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/acps.12458","article-title":"The role of inflammation in suicidal behaviour","volume":"132","author":"Brundin","year":"2015","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"10.1016\/j.jaad.2024.02.039_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/09546634.2017.1395800","article-title":"Epidemiology of mental health comorbidity in psoriasis","volume":"29","author":"Wu","year":"2018","journal-title":"J Dermatol Treat"},{"issue":"4","key":"10.1016\/j.jaad.2024.02.039_bib6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2024.02.039_bib7","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jdv.14175","article-title":"The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis","volume":"31","author":"Wu","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2024.02.039_bib8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/bjd.14633","article-title":"Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort study","volume":"175","author":"Egeberg","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2024.02.039_bib9","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"issue":"10273","key":"10.1016\/j.jaad.2024.02.039_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"issue":"10273","key":"10.1016\/j.jaad.2024.02.039_bib19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2024.02.039_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2024.02.039_bib21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/bjd\/ljad035","article-title":"Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial","volume":"188","author":"Strober","year":"2023","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.02.039_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2024.02.039_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/bjd\/ljad429","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled data from up to three years of treatment in randomized phase 3 trials","volume":"190","author":"Gordon","year":"2024","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2024.02.039_bib25","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","article-title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","volume":"59","author":"Genovese","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2024.02.039_bib26","doi-asserted-by":"crossref","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"issue":"14","key":"10.1016\/j.jaad.2024.02.039_bib27","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2024.02.039_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.02.039_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.02.039_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jdin.2022.08.010","article-title":"Examining worldwide postmarketing suicides from biologics used for psoriasis with a focus on brodalumab: a cross-sectional analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"9","author":"Yeroushalmi","year":"2022","journal-title":"JAAD Int"},{"issue":"4","key":"10.1016\/j.jaad.2024.02.039_bib32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2024.02.039_bib33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis - results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2024.02.039_bib43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.02.039_bib44","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study","volume":"83","author":"Blauvelt","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.02.039_bib45","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjd.20827","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study","volume":"186","author":"Oliver","year":"2022","journal-title":"Br J Dermatol"},{"issue":"16","key":"10.1016\/j.jaad.2024.02.039_bib47","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jpsychires.2010.04.025","article-title":"Feasibility and validation of a computer-automated Columbia-Suicide Severity Rating Scale using interactive voice response technology","volume":"44","author":"Mundt","year":"2010","journal-title":"J Psychiatr Res"},{"issue":"12","key":"10.1016\/j.jaad.2024.02.039_bib48","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"9","key":"10.1016\/j.jaad.2024.02.039_bib50","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"6","key":"10.1016\/j.jaad.2024.02.039_bib51","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"10.1016\/j.jaad.2024.02.039_bib52","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.02.039_bib53","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/bjd\/ljad115","article-title":"Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure","volume":"189","author":"Lebwohl","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2024.02.039_bib54","doi-asserted-by":"crossref","first-page":"adv00683","DOI":"10.2340\/actadv.v102.1993","article-title":"Safety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trials","volume":"102","author":"Reich","year":"2022","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2024.02.039_bib57","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/jdv.18565","article-title":"Increased risk of suicidality in patients with psoriasis: a Nationwide cohort study in Korea","volume":"37","author":"Kim","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2024.02.039_bib60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.02.039_bib61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224004389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224004389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T06:37:15Z","timestamp":1722321435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224004389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0190962224004389"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.02.039","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2\/3 randomized trials","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.02.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}